Accolade And 2 Other Penny Stocks To Watch On US Exchanges

As major U.S. indexes experience a downturn, driven by disappointing earnings reports from big tech companies, investors are exploring alternative opportunities in the market. Penny stocks, often representing smaller or newer companies, continue to attract attention despite their vintage label. These stocks can offer surprising value and growth potential when backed by strong financials, making them an intriguing option for those seeking under-the-radar investment opportunities.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.799	$5.75M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$3.19	$534.34M	★★★★★★
RLX Technology (NYSE:RLX)	$1.63	$2.12B	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.575	$50.82M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
MIND C.T.I (NasdaqGM:MNDO)	$1.88	$39.56M	★★★★★★
ARC Document Solutions (NYSE:ARC)	$3.41	$147.91M	★★★★★★
Commercial Vehicle Group (NasdaqGS:CVGI)	$3.01	$99.68M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$1.10	$98.93M	★★★★★☆
So-Young International (NasdaqGM:SY)	$1.25	$97.93M	★★★★☆☆

Click here to see the full list of 756 stocks from our US Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

Accolade (NasdaqGS:ACCD)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Accolade, Inc. develops and provides personalized, technology-enabled solutions to help individuals navigate the healthcare system and workplace benefits in the United States, with a market cap of approximately $265.77 million.

Operations: Accolade's revenue is primarily derived from its Pharmacy Services segment, totaling $441.03 million.

Market Cap: $265.77M

Accolade, Inc. operates with a market cap of approximately US$265.77 million and has shown revenue growth, reporting US$106.36 million in sales for the second quarter of 2024, up from the previous year. Despite being unprofitable with a net loss of US$23.93 million for the same period, its short-term assets exceed both short and long-term liabilities, indicating financial resilience. The company is trading at a significant discount to estimated fair value and has sufficient cash runway for over three years based on current free cash flow trends. However, shareholders have faced dilution recently as shares outstanding increased by 5.6%.

• Click to explore a detailed breakdown of our findings in Accolade's financial health report.
• Learn about Accolade's future growth trajectory here.

Accuray (NasdaqGS:ARAY)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for tumor treatment across various global regions, with a market cap of approximately $186.51 million.

Operations: The company's revenue is primarily derived from its proprietary medical devices used in radiation therapy, amounting to $446.55 million.

Market Cap: $186.51M

Accuray Incorporated, with a market cap of US$186.51 million, focuses on delivering innovative radiation therapy systems and reported revenue of US$446.55 million for the fiscal year ending June 2024. Despite being unprofitable, with net losses increasing over five years at 27.4% annually, its short-term assets cover liabilities effectively. The company has faced shareholder dilution recently and carries high debt levels with a net debt to equity ratio of 229.8%. Accuray's stock is considered undervalued compared to industry peers and analysts agree on potential price growth; however, volatility remains high amidst recent executive changes and delayed SEC filings.

• Get an in-depth perspective on Accuray's performance by reading our balance sheet health report here.
• Assess Accuray's future earnings estimates with our detailed growth reports.

Protalix BioTherapeutics (NYSEAM:PLX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system, with a market cap of $86.04 million.

Operations: Protalix BioTherapeutics has not reported any specific revenue segments.

Market Cap: $86.04M

Protalix BioTherapeutics, with a market cap of US$86.04 million, is navigating financial challenges typical of penny stocks. Despite being unprofitable, it has reduced losses by 25.2% annually over five years and maintains a stable weekly volatility at 8%. Its short-term assets of US$77.4 million exceed both its long-term liabilities and short-term obligations, providing some financial stability. The company has sufficient cash runway for more than three years even if cash flow decreases slightly each year. However, shareholders have been diluted recently as total shares outstanding increased by 2.7%, reflecting potential capital-raising activities to support operations amidst revenue declines.

• Dive into the specifics of Protalix BioTherapeutics here with our thorough balance sheet health report.
• Gain insights into Protalix BioTherapeutics' future direction by reviewing our growth report.

Make It Happen

• Navigate through the entire inventory of 756 US Penny Stocks here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com